Cannabis and Epilepsy
Cannabis-based medicines have emerged over the last decade as an important supplemental treatment option for certain neurological conditions. One of the most notable areas of research has been epilepsy, particularly severe and treatment-resistant forms such as Dravet syndrome and Lennox-Gastaut syndrome. While conventional antiepileptic drugs remain the foundation of treatment, cannabidiol (CBD) therapies have shown meaningful benefits for some patients whose seizures are difficult to control with existing medications alone.
In some rare epileptic disorders, treatment choices are limited and seizure control can be challenging. The discovery that CBD may help reduce seizure frequency in specific patient groups has therefore been considered an important development in epilepsy research.
In 2018, Epidiolex—an oral cannabidiol medication—became the first cannabis-derived drug approved by the U.S. Food and Drug Administration (FDA) for certain seizure disorders. The approval marked a significant milestone for cannabinoid-based medicine and followed randomized, placebo-controlled clinical trials demonstrating reductions in seizure frequency among patients with severe epilepsy. Importantly, CBD is generally used alongside existing antiepileptic medications rather than as a replacement therapy.
Several U.S. states initially included epilepsy among qualifying conditions for medical cannabis access, particularly for pediatric patients with treatment-resistant seizures. Over time, access expanded, and today epilepsy remains one of the most widely recognized medical indications for cannabinoid-based treatments in regulated medical cannabis programs.
How Does Cannabis Help Stop Seizures?
It is not yet fully understood how CBD helps reduce epileptic seizures.
Seizures occur when abnormal electrical activity disrupts normal signaling in the brain. Researchers believe CBD’s antiseizure effects likely involve interactions with the body’s endocannabinoid system—a biological signaling network involved in regulating functions such as sleep, appetite, pain perception, and immune response.
Current evidence suggests that CBD may influence several receptor systems connected to neuronal signaling. Rather than directly activating cannabinoid receptors in the same way as THC, cannabidiol appears to modulate multiple pathways linked to neuronal excitability.
Animal studies indicate that CBD may reduce excessive neuron activity by acting on specific receptor groups associated with calcium signaling and neurotransmitter release. However, scientists continue to investigate the precise biological mechanisms responsible for its anticonvulsant effects.
A 2015 open-label clinical study involving 162 children and young adults aged 1 to 30 with treatment-resistant epilepsy found that cannabidiol treatment was associated with reduced seizure frequency in many participants. Researchers also reported an acceptable safety profile, though they emphasized the need for controlled trials—which later informed regulatory approval.
CBD for Dravet Syndrome
Dravet syndrome is a rare and severe form of epilepsy in which seizures often respond poorly to conventional medication. Symptoms typically begin during infancy, often between four and twelve months of age, and early seizures are frequently associated with fever.
Evidence supporting CBD treatment comes from randomized clinical trials comparing Epidiolex with placebo in patients aged 2 to 18. Participants receiving cannabidiol experienced a significant reduction in seizure frequency—approximately a 39 percent decrease on average—compared with a 17 percent reduction observed in the placebo group. These findings contributed to FDA approval for this condition.
CBD for Lennox-Gastaut syndrome
Lennox-Gastaut syndrome is another severe childhood epilepsy, accounting for roughly 5 percent of pediatric epilepsy cases. Seizures usually begin before the age of four and can be particularly difficult to manage.
Clinical trials evaluating Epidiolex found that participants receiving cannabidiol experienced substantially fewer seizures compared with placebo groups. In one major study, seizure frequency decreased by about 44 percent among patients taking CBD, compared with a 22 percent reduction in controls.
Additional studies examining different dosage levels confirmed a consistent trend toward seizure reduction, even at lower therapeutic doses.
CBD for Other Types of Seizures
Research has also explored cannabidiol treatment for seizures associated with tuberous sclerosis complex, a genetic condition characterized by noncancerous tumor growth that can affect the brain and other organs.
Clinical trials involving 148 patients reported a median reduction in seizure frequency of approximately 48 percent among those receiving CBD treatment. As with other epilepsy syndromes, cannabidiol was used as an add-on therapy alongside standard antiepileptic medications.
Using CBD in Epilepsy Treatment
According to prescribing guidelines for Epidiolex, physicians typically begin treatment with low doses and gradually adjust them based on individual response and tolerance. Because epilepsy varies widely between patients, treatment plans must be personalized and carefully monitored by medical professionals.
Not all patients respond equally to cannabidiol therapy, and in some cases seizure frequency may not improve or may temporarily worsen. Abrupt discontinuation is generally avoided, as sudden changes in treatment can increase seizure risk.
CBD may also interact with other antiepileptic medications, potentially strengthening or reducing their effects. For this reason, clinicians often monitor patients closely and may adjust accompanying treatments when necessary.
Commonly reported side effects include sleepiness, fatigue, diarrhea, and reduced appetite. Clinical studies have also shown that cannabidiol can affect liver enzyme levels in some patients, which is why periodic medical monitoring may be recommended during treatment.
Treatment with cannabidiol should always be initiated and supervised by a qualified neurologist or epilepsy specialist. Medical professionals evaluate treatment response, monitor potential side effects, and determine appropriate dosing adjustments based on each patient’s condition.
A Developing Area of Research
While cannabidiol represents an important therapeutic advance for some individuals with treatment-resistant epilepsy, it is not a universal solution. Current scientific evidence supports its use primarily in specific epilepsy syndromes, and researchers continue to investigate which patients are most likely to benefit.
Ongoing studies are exploring how cannabinoids interact with the brain, how long-term treatment affects outcomes, and how cannabinoid therapies may fit into broader epilepsy care. As research progresses, CBD remains both a promising and carefully studied addition to modern epilepsy treatment.
Read more from Soft Secrets:
- Cannabis and Children: Medicine or Risk?
- Dr. Sanjay Gupta: A Decade of “Weed”
- The Cannabis Conversation Parents Can’t Avoid
Last updated March 22, 2026
S
Stephen Andrews
